Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00842-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Liezl Gibhard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, 1-Phosphatidylinositol 4-Kinase, Disease Models, Animal. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Technology Innovation Agency (TIA), Strategic Health Innovation Partnerships (SHIP) unit of the South African Medical Research Council (SAMRC), Medicines for Malaria Venture (MMV).
Abstract (Originalsprache)
UCT594 is a 2-aminopyrazine carboxylic acid Plasmodium phosphatidylinositol 4-kinase inhibitor with potent asexual blood-stage activity, the potential for interrupting transmission, as well as liver-stage activities. Herein, we investigated pharmacokinetic/pharmacodynamic (PK/PD) relationships relative to blood-stage activity toward predicting the human dose. Dose-fractionation studies were conducted in the Plasmodium falciparum NSG mouse model to determine the PK/PD indices of UCT594, using the in vivo minimum parasiticidal concentration as a threshold. UCT594 demonstrated concentration-dependent killing in the P. falciparum -infected NSG mouse model. Using this data and the preclinical pharmacokinetic data led to a low predicted human dose of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
- Independent Researcher, Kent, United Kingdom.
- Medicines for Malaria Venture, ICC, Geneva, Switzerland.
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa.
ORCID-Profile: Liezl Gibhard, Gregory S Basarab
Förderung
- Technology Innovation Agency (TIA)
- Strategic Health Innovation Partnerships (SHIP) unit of the South African Medical Research Council (SAMRC)
- Medicines for Malaria Venture (MMV)
- Neville Isdell
- South African National Research Foundation
Zitieren
APA
Gibhard, L., Njoroge, M., Mulubwa, M., Lawrence, N., Smith, D., Duffy, J., Le Manach, C., Brunschwig, C., Taylor, D., van der Westhuyzen, R., Street, L. J., Basarab, G. S., & Chibale, K. (2024). Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00842-24
Vancouver
Gibhard L, Njoroge M, Mulubwa M, Lawrence N, Smith D, Duffy J, et al. Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00842-24
BibTeX
@article{Gibhard2024,
author = {Gibhard, Liezl and Njoroge, Mathew and Mulubwa, Mwila and Lawrence, Nina and Smith, Dennis and Duffy, James and Le Manach, Claire and Brunschwig, Christel and Taylor, Dale and van der Westhuyzen, Renier and Street, Leslie J and Basarab, Gregory S and Chibale, Kelly},
title = {Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00842-24}
}
EUVIMED